Tempus AI, Inc. (TEM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Why Tempus AI Stock Is Skyrocketing Today
Shares of Tempus AI (TEM 17.39%) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday.
Tempus AI: Cooldown Arrived (Rating Upgrade)
Tempus AI is trading near yearly lows despite strong growth prospects, driven by the Ambry Genetics acquisition and robust organic growth. The company has innovative AI diagnostic services, including new cancer tests and CMS-approved algorithms, positioning it for continued 25% annual growth. TEM stock has a market cap of ~$7 billion and trades at 4.5x sales, offering compelling value and growth potential for investors.
Thermo Fisher Stock Benefits From the Launch of Krios 5 Cryo-TEM
TMO launches the Krios 5 Cryo-TEM, boosting productivity and performance with enhanced automation.
Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock?
The February 2025 acquisition of Ambry Genetics further expands TEM's genomics capabilities with a West Coast lab and enhanced inherited risk testing.
Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Tempus AI's financials have significantly improved, with positive cash flow expected next quarter and strong revenue growth projected for FY25. Q4FY24 saw record revenues, driven by a 35.8% YoY growth, with the Data & Services segment growing by 44.6% YoY. FY24 revenues hit an all-time high of $693.4 million, with major agreements signed and the launch of the AI-enabled health app, Olivia.
Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?
The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.
Should Investors Buy Tempus AI Stock Right Now?
Tempus AI (TEM -11.18%) is utilizing artificial intelligence to deliver better healthcare outcomes.
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.
Tempus AI: Buying The Dip After 2025 Guidance Raise
Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results, presenting a buying opportunity due to raised 2025 revenue guidance. The company, a leader in healthcare AI, focuses on revenue growth and customer adoption, with a proprietary data model for personalized healthcare treatment. Despite stock volatility, Tempus AI's 30% organic revenue growth and Ambry acquisition integration highlight its long-term potential in the healthcare AI market.
Tempus AI Is a Buy, If You Can Handle the Volatility
Tempus AI NASDAQ: TEM is an emerging AI player in the healthcare field with a robust outlook for long-term growth and profitability. The company uses AI to manage patient testing and help physicians generate timely diagnoses and treatment regimens.
Tempus AI Down 13%- Is It Time to Buy?
Shares of Nancy Pelosi's favorite artificial intelligence stock Tempus AI (NASDAQ:TEM) are falling more than 13% in morning trading after reporting fourth quarter and full-year 2024 earnings results yesterday after the market closed.
